Insilico Medicine Nominates AI-Designed ISM9077 as Preclinical Candidate for Ocular Diseases
HONG KONG, August 5, 2026 Insilico Medicine has announced the nomination of ISM9077 as its 32nd Preclinical Candidate (PCC)...
dry AMD
Advertisement
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
Belite Bio Highlights DRAGON Trial at ISCEV and ASRS
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
Ocugen OCU410 Gene Therapy Cuts GA Progression
MALVERN, Pennsylvania, USA | March 24, 2026 In a major breakthrough for retinal disease treatment, Ocugen, Inc. has announced...
Advertisements
PulseSight Completes Phase I Dosing of PST-611 in Dry AMD
Paris, France | January 22, 2026 — PulseSight Therapeutics, a Paris-based clinical-stage biotechnology company, has announced the successful completion...
Alzheimer’s and Eye Drug Updates Highlight InMed FY2025
Vancouver, BC, September 23, 2025 – InMed Pharmaceuticals has reported its full‐year fiscal 2025 financial results and provided a...
Advertisement
